Skip to main content
Erschienen in: Supportive Care in Cancer 2/2010

01.02.2010 | Original Article

Marine phospholipids—a promising new dietary approach to tumor-associated weight loss

verfasst von: Lenka A. Taylor, Lars Pletschen, Jann Arends, Clemens Unger, Ulrich Massing

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

Advanced tumor disease very often evokes excessive loss of body weight. Among others, fish oil or marine fatty acid ethyl esters were investigated for treatment of cancer cachexia with controversial results. In this study, a new formulation of marine fatty acids was investigated, the marine phospholipids, with more than 50% of phospholipid-bound fatty acids being eicosapentaenoic and docosahexaenoic acid.

Materials and methods

Thirty-one tumor patients with various tumor entities suffering from weight loss were asked to take marine phospholipids (1.5 g/day) as softgel capsules for a period of 6 weeks. Compliance, body weight, appetite, and quality of life as well as the fatty acid profile in plasma and blood cells were monitored; 17 patients could be analyzed.

Main results

Marine phospholipids were very well accepted; low-dose supplementation resulted in a significant increase of eicosapentaenoic and docosahexaenoic acid in plasma phospholipids; therefore, significantly reducing the n − 6 to n − 3 fatty acid ratio. A stabilization of body weight was achieved (median weight change of +0.6% after 6 weeks), while appetite and quality of life improved.

Conclusions

These promising first results encourage further investigation of marine phospholipids in cancer care.
Literatur
2.
Zurück zum Zitat Tranmer JE, Heyland D, Dudgeon D, Groll D, Squires-Graham M, Coulson K (2003) Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manage 25:420–429. doi:10.1016/S0885-3924(03)00074-5 CrossRefPubMed Tranmer JE, Heyland D, Dudgeon D, Groll D, Squires-Graham M, Coulson K (2003) Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manage 25:420–429. doi:10.​1016/​S0885-3924(03)00074-5 CrossRefPubMed
5.
Zurück zum Zitat Jatoi A (2006) Pharmacologic therapy for the cancer anorexia/weight loss syndrome: a data-driven, practical approach. J Support Oncol 4:499–502PubMed Jatoi A (2006) Pharmacologic therapy for the cancer anorexia/weight loss syndrome: a data-driven, practical approach. J Support Oncol 4:499–502PubMed
10.
Zurück zum Zitat Morley JE, Thomas DR, Wilson MM (2006) Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83:735–743PubMed Morley JE, Thomas DR, Wilson MM (2006) Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83:735–743PubMed
15.
Zurück zum Zitat Endres S, Ghorbani R, Kelley VE et al (1989) The effect of dietary supplementation with n−3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 320:265–271PubMed Endres S, Ghorbani R, Kelley VE et al (1989) The effect of dietary supplementation with n−3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 320:265–271PubMed
16.
Zurück zum Zitat Wigmore SJ, Fearon KC, Maingay JP, Ross JA (1997) Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond) 92:215–221 Wigmore SJ, Fearon KC, Maingay JP, Ross JA (1997) Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond) 92:215–221
18.
Zurück zum Zitat Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC (1999) The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 81:80–86. doi:10.1038/sj.bjc.6690654 CrossRefPubMed Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC (1999) The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 81:80–86. doi:10.​1038/​sj.​bjc.​6690654 CrossRefPubMed
20.
Zurück zum Zitat Bruera E, Strasser F, Palmer JL et al (2003) Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 21:129–134. doi:10.1200/JCO.2003.01.101 CrossRefPubMed Bruera E, Strasser F, Palmer JL et al (2003) Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 21:129–134. doi:10.​1200/​JCO.​2003.​01.​101 CrossRefPubMed
21.
Zurück zum Zitat Fearon KC, Von Meyenfeldt MF, Moses AG et al (2003) Effect of a protein and energy dense n−3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52:1479–1486. doi:10.1136/gut.52.10.1479 CrossRefPubMed Fearon KC, Von Meyenfeldt MF, Moses AG et al (2003) Effect of a protein and energy dense n−3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52:1479–1486. doi:10.​1136/​gut.​52.​10.​1479 CrossRefPubMed
23.
Zurück zum Zitat Burns CP, Halabi S, Clamon GH et al (1999) Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 5:3942–3947PubMed Burns CP, Halabi S, Clamon GH et al (1999) Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 5:3942–3947PubMed
26.
Zurück zum Zitat Persson EM, Nilsson RG, Hansson GI et al (2006) A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. Pharm Res 23:742–751. doi:10.1007/s11095-006-9607-z CrossRefPubMed Persson EM, Nilsson RG, Hansson GI et al (2006) A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. Pharm Res 23:742–751. doi:10.​1007/​s11095-006-9607-z CrossRefPubMed
27.
Zurück zum Zitat Amate L, Gil A, Ramirez M (2001) Feeding infant piglets formula with long-chain polyunsaturated fatty acids as triacylglycerols or phospholipids influences the distribution of these fatty acids in plasma lipoprotein fractions. J Nutr 131:1250–1255PubMed Amate L, Gil A, Ramirez M (2001) Feeding infant piglets formula with long-chain polyunsaturated fatty acids as triacylglycerols or phospholipids influences the distribution of these fatty acids in plasma lipoprotein fractions. J Nutr 131:1250–1255PubMed
28.
Zurück zum Zitat Zierenberg O, Grundy SM (1982) Intestinal absorption of polyenephosphatidylcholine in man. J Lipid Res 23:1136–1142PubMed Zierenberg O, Grundy SM (1982) Intestinal absorption of polyenephosphatidylcholine in man. J Lipid Res 23:1136–1142PubMed
30.
Zurück zum Zitat Oette K, Kuhn G, Romer A, Niemann R, Gundermann KJ, Schumacher R (1995) Arzneimittelforschung 45:875–879. Absorption of di-linoleoylphosphatidylcholine after oral administration Oette K, Kuhn G, Romer A, Niemann R, Gundermann KJ, Schumacher R (1995) Arzneimittelforschung 45:875–879. Absorption of di-linoleoylphosphatidylcholine after oral administration
31.
Zurück zum Zitat Wijendran V, Huang MC, Diau GY, Boehm G, Nathanielsz PW, Brenna JT (2002) Efficacy of dietary arachidonic acid provided as triglyceride or phospholipid as substrates for brain arachidonic acid accretion in baboon neonates. Pediatr Res 51:265–272. doi:10.1203/00006450-200203000-00002 CrossRefPubMed Wijendran V, Huang MC, Diau GY, Boehm G, Nathanielsz PW, Brenna JT (2002) Efficacy of dietary arachidonic acid provided as triglyceride or phospholipid as substrates for brain arachidonic acid accretion in baboon neonates. Pediatr Res 51:265–272. doi:10.​1203/​00006450-200203000-00002 CrossRefPubMed
32.
Zurück zum Zitat Goustard-Langelier B, Guesnet P, Durand G, Antoine JM, Alessandri JM (1999) n-3 and n-6 fatty acid enrichment by dietary fish oil and phospholipid sources in brain cortical areas and nonneural tissues of formula-fed piglets. Lipids 34:5–16. doi:10.1007/s11745-999-331-6 CrossRefPubMed Goustard-Langelier B, Guesnet P, Durand G, Antoine JM, Alessandri JM (1999) n-3 and n-6 fatty acid enrichment by dietary fish oil and phospholipid sources in brain cortical areas and nonneural tissues of formula-fed piglets. Lipids 34:5–16. doi:10.​1007/​s11745-999-331-6 CrossRefPubMed
34.
Zurück zum Zitat Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917PubMed Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917PubMed
35.
Zurück zum Zitat Taylor LA, Arends J, Hodina AK, Unger C, Massing U (2007) Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis 6:17. doi:10.1186/1476-511X-6-17 CrossRefPubMed Taylor LA, Arends J, Hodina AK, Unger C, Massing U (2007) Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis 6:17. doi:10.​1186/​1476-511X-6-17 CrossRefPubMed
36.
Zurück zum Zitat Taylor LA, Ziroli V, Massing U (2008) Analysis of fatty acid profile in plasma phospholipids by solid-phase extraction in combination with GC. Eur J Lipid Sci Technol (in press)CrossRefPubMed Taylor LA, Ziroli V, Massing U (2008) Analysis of fatty acid profile in plasma phospholipids by solid-phase extraction in combination with GC. Eur J Lipid Sci Technol (in press)CrossRefPubMed
37.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376. doi:10.1093/jnci/85.5.365 CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376. doi:10.​1093/​jnci/​85.​5.​365 CrossRefPubMed
38.
Zurück zum Zitat Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed
39.
Zurück zum Zitat Schwemmer M, Aho H, Michel JB (2001) Interleukin-1beta-induced type IIA secreted phospholipase A2 gene expression and extracellular activity in rat vascular endothelial cells. Tissue Cell 33:233–240. doi:10.1054/tice.2000.0163 CrossRefPubMed Schwemmer M, Aho H, Michel JB (2001) Interleukin-1beta-induced type IIA secreted phospholipase A2 gene expression and extracellular activity in rat vascular endothelial cells. Tissue Cell 33:233–240. doi:10.​1054/​tice.​2000.​0163 CrossRefPubMed
40.
44.
Zurück zum Zitat Kriat M, Vion-Dury J, Confort-Gouny S et al (1993) Analysis of plasma lipids by NMR spectroscopy: application to modifications induced by malignant tumors. J Lipid Res 34:1009–1019PubMed Kriat M, Vion-Dury J, Confort-Gouny S et al (1993) Analysis of plasma lipids by NMR spectroscopy: application to modifications induced by malignant tumors. J Lipid Res 34:1009–1019PubMed
45.
Zurück zum Zitat Kuliszkiewicz-Janus M, Janus W, Baczynski S (1996) Application of 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers. Anticancer Res 16:1587–1594PubMed Kuliszkiewicz-Janus M, Janus W, Baczynski S (1996) Application of 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers. Anticancer Res 16:1587–1594PubMed
47.
Zurück zum Zitat Sullentrop F, Moka D, Neubauer S et al (2002) 31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma. NMR Biomed 15:60–68. doi:10.1002/nbm.758 CrossRefPubMed Sullentrop F, Moka D, Neubauer S et al (2002) 31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma. NMR Biomed 15:60–68. doi:10.​1002/​nbm.​758 CrossRefPubMed
48.
Zurück zum Zitat Boggs KP, Rock CO, Jackowski S (1995) Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J Biol Chem 270:7757–7764. doi:10.1074/jbc.270.13.7757 CrossRefPubMed Boggs KP, Rock CO, Jackowski S (1995) Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J Biol Chem 270:7757–7764. doi:10.​1074/​jbc.​270.​13.​7757 CrossRefPubMed
50.
Zurück zum Zitat Balsinde J, Bianco ID, Ackermann EJ, Conde-Frieboes K, Dennis EA (1995) Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. Proc Natl Acad Sci USA 92:8527–8531. doi:10.1073/pnas.92.18.8527 CrossRefPubMed Balsinde J, Bianco ID, Ackermann EJ, Conde-Frieboes K, Dennis EA (1995) Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. Proc Natl Acad Sci USA 92:8527–8531. doi:10.​1073/​pnas.​92.​18.​8527 CrossRefPubMed
52.
Metadaten
Titel
Marine phospholipids—a promising new dietary approach to tumor-associated weight loss
verfasst von
Lenka A. Taylor
Lars Pletschen
Jann Arends
Clemens Unger
Ulrich Massing
Publikationsdatum
01.02.2010
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0640-4

Weitere Artikel der Ausgabe 2/2010

Supportive Care in Cancer 2/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.